Evaluating the effect of 2 medications that treat glaucoma in patients of early glaucoma.

Not Applicable

• Conditions: Health Condition 1: H408- Other glaucoma

• Registration Number: CTRI/2024/03/064598
• Lead Sponsor: Dr Rajendra Prasad Centre for Ophthalmic Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 April 2024

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Preperimetric Glaucoma-

Age over 40 years

Open angle in gonioscopy

Baseline IOP = 25mmHg

Best-corrected visual acuity 20/40 or better (refractive error ± 5.0D spherical; ± 3.0D cylinder)

Abnormal circumpapillary RNFL thickness (cpRNFLT) in at least one quadrant on OCT scan

A visual field within the normal limits of a glaucoma hemifield test, with pattern standard deviation (PSD) greater than 5%, confirmed in at least two examinations

Early Glaucoma-

BCVA 20/40 or more (refractive error ± 5.0D spherical; ± 3.0D cylinder)

Open angles on gonioscopy

Baseline IOP = 25mmHg

Features suggestive of glaucomatous optic neuropathy such as cup-disc ratio >0.6 and any diffuse or focal neuroretinal rim thinning 2 consecutive abnormal visual field tests defined as PSD outside 95% normal confidence limits and a GHT classified as ‘‘outside normal limits’’ as defined by the Hodapp-Parrish-Anderson (HPA) criteria for early glaucoma

Exclusion Criteria

Patients with moderate or advanced glaucoma (MD worse than -6 dB)

Patients with media opacity precluding good-quality OCT scans such as corneal opacity, cataracts, etc.

History of intraocular diseases, complicated intraocular surgery, secondary glaucoma

Age < 40 years

Coexisting retinal disease (for example, diabetic retinopathy)

Other diseases affecting visual field

Patients on vasodilatory drugs such as Nitroglycerin

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Vessel Density(ONH AND MACULAR) USING OCTATimepoint: Day 1, 4 months, 8 months, 12 months(if possible)

Secondary Outcome Measures

Name	Time	Method
Flux indexTimepoint: Day 1, 4 months, 8 months, 12 months(if possible);Macular Flow IndexTimepoint: Day 1, 4 months, 8 months, 12 months(if possible);pRNFL ThicknessTimepoint: Day 1, 4 months, 8 months, 12 months(if possible);Visual Field ChangesTimepoint: Day 1, 4 months, 8 months, 12 months(if possible)